Beta-Blockers in Post-MI Patients: Need to Re-consider?
Keywords:
acute myocardial infarction, beta-blockers, heart failure, cardiogenic shockAbstract
International clinical practice guidelines recommend early introduction and continued treatment with beta-blockers for all patients without contraindications after STEMI. Although there seemed to be little question that patients with STEMI, regardless of revascularization strategy, derive substantial benefits from both long- and short-term beta-blockade, there has been a paucity of high quality evidence supporting this notion and the majority of data predate modern reperfusion therapy and current medical management strategies with statins and antiplatelet agents. Recently published data question this “one-size-fits-all” approach, showing that the use of beta-blockers increased the risk of heart failure and cardiogenic shock with no mortality benefit.Downloads
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
